Efficacy, acceptability, and safety of adjunctive aripiprazole in treatment-resistant depression: a meta-analysis of randomized controlled trials

References

• WhitefordHADegenhardtLRehmJGlobal burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010Lancet201338299041575158623993280
   PubMed Web of Science ®Google Scholar
• CallahanCMKroenkeKCounsellSRIMPACT InvestigatorsTreatment of depression improves physical functioning in older adultsJ Am Geriatr Soc200553336737315743276
   PubMed Web of Science ®Google Scholar
• GalloJJMoralesKHBognerHRLong term effect of depression care management on mortality in older adults: follow-up of cluster randomized clinical trial in primary careBMJ2013346f257023738992
   PubMed Web of Science ®Google Scholar
• FavaMDiagnosis and definition of treatment-resistant depressionBiol Psychiatry200353864965912706951
   PubMed Web of Science ®Google Scholar
• TrivediMHRushAJWisniewskiSRSTAR*D Study TeamEvaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practiceAm J Psychiatry20061631284016390886
   PubMed Web of Science ®Google Scholar
• NemeroffCBThe burden of severe depression: a review of diagnostic challenges and treatment alternativesJ Psychiatr Res2007413–418920616870212
   PubMed Web of Science ®Google Scholar
• SackeimHAThe definition and meaning of treatment-resistant depressionJ Clin Psychiatry200162Suppl 161017
   PubMedGoogle Scholar
• FavaMRushAJCurrent status of augmentation and combination treatments for major depressive disorder: a literature review and a proposal for a novel approach to improve practicePsychother Psychosom200675313915316636629
   PubMed Web of Science ®Google Scholar
• MaustDTOslinDWThaseMEGoing beyond antidepressant monotherapy for incomplete response in nonpsychotic late-life depression: a critical reviewAm J Geriatr Psychiatry2013211097398623567381
   PubMed Web of Science ®Google Scholar
• CooperCKatonaCLyketsosKA systematic review of treatments for refractory depression in older peopleAm J Psychiatry2011168768168821454919
   PubMed Web of Science ®Google Scholar
• LamRWKennedySHGrigoriadisSCanadian Network for Mood and Anxiety Treatments (CANMAT)Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. PharmacotherapyJ Affect Disord2009117Suppl 1S26S4319674794
   PubMed Web of Science ®Google Scholar
• FleurenceRWilliamsonRJingYA systematic review of augmentation strategies for patients with major depressive disorderPsychopharmacol Bull2009423579019752841
   PubMed Web of Science ®Google Scholar
• BurrisKDMolskiTFXuCAripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptorsJ Pharmacol Exp Ther2002302138138912065741
   PubMed Web of Science ®Google Scholar
• JordanSKoprivicaVChenRTottoriKKikuchiTAltarCAThe antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptorEur J Pharmacol2002441313714012063084
   PubMed Web of Science ®Google Scholar
• ShapiroDARenockSArringtonEAripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacologyNeuropsychopharmacology20032881400141112784105
   PubMed Web of Science ®Google Scholar
• JonDIKimDHSeoHJAugmentation of aripiprazole for depressed patients with an inadequate response to antidepressant treatment: a 6-week prospective, open-label, multicenter studyClin Neuropharmacol201336515716124045606
   PubMed Web of Science ®Google Scholar
• MoherDLiberatiATetzlaffJAltmanDGPreferred reporting items for systematic reviews and meta-analyses: the PRISMA statementBMJ2009339b253519622551
   PubMed Web of Science ®Google Scholar
• HigginsJPAltmanDGGotzschePCCochrane Statistical Methods GroupThe cochrane collaboration’s tool for assessing risk of bias in randomised trialsBMJ2011343d592822008217
   PubMed Web of Science ®Google Scholar
• GuyattGHOxmanADVistGEGRADE Working GroupGRADE: an emerging consensus on rating quality of evidence and strength of recommendationsBMJ2008336765092492618436948
   PubMed Web of Science ®Google Scholar
• HigginsJPThompsonSGDeeksJJAltmanDGMeasuring inconsistency in meta-analysesBMJ2003327741455756012958120
   PubMed Web of Science ®Google Scholar
• DerSimonianRLairdNMeta-analysis in clinical trialsControl Clin Trials1986731771883802833
   PubMedGoogle Scholar
• MantelNHaenszelWStatistical aspects of the analysis of data from retrospective studies of diseaseJ Natl Cancer Inst195922471974813655060
   PubMed Web of Science ®Google Scholar
• BeggCBMazumdarMOperating characteristics of a rank correlation test for publication biasBiometrics1994504108811017786990
   PubMed Web of Science ®Google Scholar
• EggerMDavey SmithGSchneiderMMinderCBias in meta-analysis detected by a simple, graphical testBMJ199731571096296349310563
   PubMed Web of Science ®Google Scholar
• FabrazzoMPerrisFMonteleonePEspositoGCatapanoFMajMAripiprazole augmentation strategy in clomipramine-resistant depressive patients: an open preliminary studyEur Neuropsychopharmacol201222213213621784621
   PubMed Web of Science ®Google Scholar
• NaylorJCKiltsJDBradfordDWA pilot randomized placebo-controlled trial of adjunctive aripiprazole for chronic PTSD in US military Veterans resistant to antidepressant treatmentInt Clin Psychopharmacol201530316717425647451
   PubMed Web of Science ®Google Scholar
• KaneriyaSHRobbins-WeltyGASmagulaSFPredictors and moderators of remission with aripiprazole augmentation in treatment-resistant late-life depression: an analysis of the IRL-GRey Randomized Clinical TrialJAMA Psychiatry201673432933626963689
   PubMed Web of Science ®Google Scholar
• YoshimuraRKishiTHoriHComparison of the efficacy between paroxetine and sertraline augmented with aripiprazole in patients with refractory major depressive disorderProgress Neuropsychopharmacol Biol Psychiatry2012392355357
   PubMed Web of Science ®Google Scholar
• FavaMMischoulonDIosifescuDA double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study)Psychother Psychosom2012812879722286203
   PubMed Web of Science ®Google Scholar
• BermanRMFavaMThaseMEAripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressantsCNS Spectr200914419720619407731
   PubMed Web of Science ®Google Scholar
• LinCHLinSHJangFLAdjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh major depressive disorder: a randomized, double-blind, controlled studyJ Clin Psychopharmacol201131556356821869699
   PubMed Web of Science ®Google Scholar
• BermanRMMarcusRNSwaninkRThe efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled studyJ Clin Psychiatry200768684385317592907
   PubMed Web of Science ®Google Scholar
• MarcusRNMcQuadeRDCarsonWHThe efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled studyJ Clin Psychopharmacol200828215616518344725
   PubMed Web of Science ®Google Scholar
• LenzeEJMulsantBHBlumbergerDMEfficacy, safety, and tolerability of augmentation pharmacotherapy with aripiprazole for treatment-resistant depression in late life: a randomised, double-blind, placebo-controlled trialLancet2015386100112404241226423182
   PubMed Web of Science ®Google Scholar
• SchüleCBaghaiTCEserDMirtazapine monotherapy versus combination therapy with mirtazapine and aripiprazole in depressed patients without psychotic features: a 4-week open-label parallel-group studyWorld J Biol Psychiatry20078211212217455104
   PubMed Web of Science ®Google Scholar
• KamijimaKHiguchiTIshigookaJADMIRE StudyGroupAripiprazole augmentation to antidepressant therapy in Japanese patients with major depressive disorder: a randomized, double-blind, placebo-controlled study (ADMIRE study)J Affect Disord2013151389990524074484
   PubMed Web of Science ®Google Scholar
• ZhouXRavindranAVQinBComparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression: systematic review and network meta-analysisJ Clin Psychiatry2015764e487e49825919841
   PubMed Web of Science ®Google Scholar
• ZhouXKeitnerGIQinBAtypical antipsychotic augmentation for treatment-resistant depression: a systematic review and network meta-analysisInt J Neuropsychopharmacol20151811pyv06026012350
   PubMed Web of Science ®Google Scholar